Table of contents
December 2003 Vol 2 No 12
In This Issue
p933 | doi:10.1038/nrd1271
Editorial: Bringing a dose of science to the art of medicine
p935 | doi:10.1038/nrd1269
News and Analysis
News
FDA guidance on pharmacogenomics data submission
p937 | doi:10.1038/nrd1274
News
First head-to-head statin results announced | Risk increase with accelerated oncology drug approvals | AstraZeneca's anticoagulant performs well | US drug prices in line with per capita income | Controversy clouds cardiovascular treatment success | Exhibition examines influence of treatments
p938 | doi:10.1038/nrd1278
News
Antidepressant use in children questioned
p939 | doi:10.1038/nrd1275
Patent watch
Elan's transgenic mouse back in the running
p940 | doi:10.1038/nrd1261
Patent watch
Interference decision upheld
p940 | doi:10.1038/nrd1276
Patent watch
Merck's acid dissolves Teva's salt
p940 | doi:10.1038/nrd1277
From the analyst's couch
'New' FDA delivers in 2003
p941 | doi:10.1038/nrd1257
Fresh from the Pipeline
Daptomycin
p943 | doi:10.1038/nrd1258
Research Highlights
Antiviral drugs: Macrocyclic inhibitor for hepatitis C
p945 | doi:10.1038/nrd1259
Antipyretic drugs: Heat relief
p946 | doi:10.1038/nrd1265
Drug delivery: Biodegradable multi-drug dispenser
p946 | doi:10.1038/nrd1272
Virtual screening: Different routes to the same answer
p947 | doi:10.1038/nrd1260
Combinatorial chemistry: New directions in chemical space
p948 | doi:10.1038/nrd1266
In brief
Lead Identification | Antiviral Drugs | High-Throughput Screening | Antibacterial Drugs
p948 | doi:10.1038/nrd1267
Reviews
Paediatric clinical trials: redressing the imbalance
Mark S. Schreiner
p949 | doi:10.1038/nrd1253
Tissue microarrays in drug discovery
Guido Sauter, Ronald Simon & Kenneth Hillan
p962 | doi:10.1038/nrd1254
GLIA: A novel drug discovery target for clinical pain
Linda R. Watkins & Steven F. Maier
p973 | doi:10.1038/nrd1251
Neuropeptide gene polymorphisms and human behavioural disorders
Akio Inui
p986 | doi:10.1038/nrd1252
Opportunities in somatostatin research: biological, chemical and therapeutic aspects
Gisbert Weckbecker, Ian Lewis, Rainer Albert, Herbert A. Schmid, Daniel Hoyer & Christian Bruns
p999 | doi:10.1038/nrd1255
Perspective
Timeline
Metabolic engineering for drug discovery and development
Chaitan Khosla & Jay D. Keasling
p1019 | doi:10.1038/nrd1256
Natureview: Reviews and comment from the nature publishing group
p1027 | doi:10.1038/nrd1273
Careers and Recruitment
Correction: Cox-2 and beyond: Approaches to prostagland in inhibition in human disease
Garret A. FitzGerald
| doi:10.1038/nrd1264
